B cells as therapeutic targets in autoimmune neurological disorders

Nature Clinical Practice Neurology

Volumn 4, Issue 10, 2008, Pages 557-567

  Dalakas, Marinos C ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; APRIL PROTEIN; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYTOKINE; EPRATUZUMAB; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; NATALIZUMAB; OCCRELIZUMAB; PLACEBO; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANAPHYLAXIS; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL MATURATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HOMEOSTASIS; HUMAN; HYPOTENSION; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; MYOPATHY; NEUROLOGIC DISEASE; NEUROPATHY; PARANEOPLASTIC NEUROPATHY; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION; STIFF MAN SYNDROME; T LYMPHOCYTE; UPREGULATION;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; B-LYMPHOCYTES; HUMANS; IMMUNOLOGIC FACTORS;

EID: 54049122104     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0901     Document Type: Review

References (64)

1. Hasler P and Zouali M (2006) B lymphocytes as therapeutic targets in systemic lupus erythematosus. Expert Opin Ther Targets 10: 803-815
2. Shlomchik MJ et al. (2001) From T to B and back again: Positive feedback in systemic autoimmune disease. Nat Rev Immunol 1: 147-153
3. Dalakas MC (2008) Invited article: Inhibition of B cell functions: implications for neurology. Neurology 70: 2252-2260
4. Browning JL (2006) B cells move to centre stage: Novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5: 564-576
5. Goldsby RA et al. (2000) Kuby Immunology, edn 4. New York: WH Freeman and Company
6. Martin F and Chan AC (2006) B cell immunobiology in disease: Evolving concepts from the clinic. Annu Rev Immunol 24: 467-496
7. Yurasov S et al. (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 201: 703-711
8. Chan OT et al. (1999) A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189: 1639-1648
9. Lanzavecchia A (1990) Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 8: 773-793
10. Lund FE et al. (2005) Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 8 25-54
11. Duddy ME et al. (2004) Distinct profiles of human B cell effector cytokines: A role in immune regulation? J Immunol 172: 3422-3427
12. Knopf PM et al. (1998) Antigen-dependent intrathecal antibody synthesis in the normal rat brain: Tissue entry and local retention of antigen-specific B cells. J Immunol 161: 692-701
13. Alter A et al. (2003) Determinants of human B cell migration across brain endothelial cells. J Immunol 170: 4497-4505
14. Meinl E et al. (2006) B lineage cells in the inflammatory central nervous system environment; migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 59: 880-892
15. + cell antibody repertoires in the cerebrospinal fluid of patients with multiple sclerosis. J Immunol 173: 649-656
16. Serafini B et al. (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14: 164-174
17. Magilozzi R et al. (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089-1104
18. Dillon SR et al. (2006) An APRIL to remember novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5: 235-246
19. Peter HH and Warnatz K (2005) Molecules involved, in T-B co-stimulation and B call homeostasis: Possible targets for an immunological intervention in autoimmunity. Expert Opin Biol Ther 5 (Suppl 1) S61-S71
20. Thangarajh M et al. (2005) Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis. J Neuroimmunol 167: 210-214
21. Krumbholz M et al. (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201: 195-200
22. Thangarajh M et al. (2007) A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis. Scand J Immunol 65: 92-98
23. Kalled SL (2006) Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 18: 290-296
24. Stohl W (2004) Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Expert Opin Ther Targets 8: 177-189
25. Huntington ND et al. (2006) A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 18: 1473-1485
26. Eisenberg R and Albert D (2006) B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol 2: 20-27
27. Edwards JC and Cambridge G (2005) Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 44: 151-156
28. Lucchinetti C et al. (2000) Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 47: 707-717
29. Frohman EM et al. (2006) Multiple sclerosis - the plaque and its pathogenesis. N Engl J Med 354: 942-955
30. Cepok S et al. (2005) Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 128: 1667-1676
31. Genain CP et al. (1999) Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5 170-175
32. Monson NL et al. (2005) Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 62: 258-264
33. Hauser S et al. (2008) B-cell depletion with rituximab in relapsing - remitting multiple sclerosis. N Engl J Med 358: 676-688
34. Bar-Or A et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol 63 395-400
35. Jarius S et al. (2008) Mechanisms of disease: Aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4: 202-214
36. Cree BA and Wingerchuk DM (2005) Acute transverse myelitis: Is the "idiopathic" form vanishing? Neurology 65: 1857-1858
37. Jacob A et al. (2007) Retrospective analysis of rituximab treatment of 24 patients with neuromyelitis optica [abstract #S32.002]. Neurology 68 (Suppi 1): A206
38. Genain C et al. (2007) An open label clinical trial of rituximab in neuromyelitis optica [abstract #S32.001]. Neurology 68 (Suppl 1): A205
39. Pranzatelli MR et al. (2004) B- and T-cell markers in opsoclonus - myoclonus syndrome: Immunophenotyping of CSF lymphocytes. Neurology 62: 1526-1532
40. Pranzatelli MR et al. (2006) Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 28: 585-593
41. Dalakas M and Engel WK (1980) Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol 37: 637-640
42. Hays AP et al. (1988) Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol 18: 231-244
43. Pestronk A et al. (2003) Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74: 485-489
44. Ruegg SJ et al. (2004) Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 63 2178-2179
45. Levine TD and Pestronk A (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 52: 1701-1704
46. Renaud S et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27: 611-615
47. Dalakas MC et al. (2007) A double-blind placebo-controlled study of rltuximab in patients with anti-MAG antibody-demyelinating polyneuropathy (A-MAG-DP) [abstract #S38.001]. Neurology 68 (Suppl 1): A214
48. A-receptor-associated protein in stiff-person syndrome. Brain 129: 3270-3276
49. Dalakas MC et al. (2001) Stiff-person syndrome: Quantification, specificity and intrathecal synthesis of GAD65 antibodies. Neurology 57: 780-785
50. Baker MR et al. (2005) Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 76: 999-1001
51. Dalakas MC and Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362: 971-982
52. Noss EH et al. (2006) Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33: 1021-1026
53. Levine TD (2005) Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum 52: 601-607
54. Wylam ME et al. (2003) Successful treatment of refractory myasthenia gravis using rituximab: A pediatric case report. J Pediatr 143: 674-677
55. Illa I et al. (2008) Rituximab in refractory myasthenia gravis: A follow-up study of patients with anti-AChR or anti-MuSK antibodies [abstract #P06.001]. Neurology 70 (Suppl 1): A301
56. Tandam R et al. (2008) Pilot trial of rituximab in myasthenia gravis [abstract #P06.002]. Neurology 70 (Suppl 1): A301
57. Frenay CL et al. (2008) Rituximab for treatment of refractory myasthenia gravis [abstact #S57.003]. Neurology 70 (Suppl 1) A427
58. Leandro MJ et al. (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54: 613-620
59. Dorner T (2006) Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 77: 3-11
60. Pescovitz MD (2006) Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant 6: 859-866.
61. Amanna IJ et al. (2007) Duration of humoral immunity to common viral and vaccine andgens. N Engl J Med 357: 1903-1915
62. Keogh KA et al. (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 262-268
63. Kleinschmidt-DeMasters BK and Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353: 369-374
64. FDA Public Health Advisory (2006) Life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment. [http://www.fda.gov/cder/drug/advisory/rituximab.htm]